preprints.org > biology and life sciences > virology > doi: 10.20944/preprints202402.0739.v2

Preprint Communication Version 2 Preserved in Portico This version is not peer-reviewed

Version 1 : Received: 12 February 2024 / Approved: 13 February 2024 / Online: 13 February 2024 (13:06:34 CET)
Version 2 : Received: 19 April 2024 / Approved: 19 April 2024 / Online: 19 April 2024 (15:21:14 CEST)

Background: given the various clinical manifestations that characterize coronavirus disease 2019 (COVID-19), the scientific community is constantly searching for biomarkers with prognostic value. Surfactant protein A (SP-A) and D (SP-D) play a crucial role in ensuring proper alveolar function and an alteration of their serum levels have been reported in several pulmonary diseases characterized by acute respiratory distress syndrome (ARDS) and pulmonary fibrosis. Consid-ering that such clinical manifestations can also occur during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, we wondered if these collectins could act as prognostic markers. Methods: in this regard, serum levels of SP-A and SP-D were measured by enzyme immunoassay in patients with SARS-CoV-2 infection (n=51) at admission (T0) and after 7 days (T1) and compared with healthy donors (n=11). Results: SP-D increased in COVID-19 patients com-pared to healthy controls during the early phases of infection, while a significant reduction was observed at T1. Stratifying SARS-CoV-2 patients according to disease severity, increased serum SP-D levels were observed in severe compared to mild patients. Conclusions: In the light of these results SP-D, but not SP-A, seems to be an eligible marker of COVID-19 pneumonia and the early detection of SP-D serum levels could be crucial for a preventive clinical management.

SP-A; SP-D; SARS-CoV-2; collectins; surfactant proteins

Biology and Life Sciences, Virology

* All users must log in before leaving a comment